REM Sleep Behavior Disorder (RBD) in Lewy Body Dementia

A Phase 2, multi-center, double-blind, placebo-controlled study evaluating nelotanserin in subjects with dementia with Lewy bodies (DLB) who are experiencing rapid eye movement (REM) sleep behavior disorder (RBD).

The efficacy, safety, and tolerability of 80 mg of nelotanserin are being evaluated over a 4-week period in approximately 60 subjects with DLB. The primary efficacy evaluation is a change in the frequency of REM sleep behaviors by the end of 4 weeks. Subjects who complete the study are eligible to receive nelotanserin in an extension study.

Compound:
Nelotanserin

Therapeutic Area(s):

  • Dementia with Lewy bodies (DLB)

For More Information:
ClinicalTrials.gov